Solifenacin Succinate clinical trials
Solifenacin Succinate is named as an intervention in 3 current clinical trials in our China and Egypt registers. 3 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Yin Ping (1). The most-studied condition is Overactive Bladder.
Where Solifenacin Succinate is approved
All regulators →Of the three regulators tracked here, the first to approve Solifenacin Succinate was the US, on 19 Nov 2004. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Solifenacin Succinate
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Solifenacin Succinate works
All drug targets →- Muscarinic acetylcholine receptor M3 antagonist AntagonistTarget: CHRM3 cholinergic receptor muscarinic 3✓ In ChEMBL and the Guide to Pharmacology
- Muscarinic acetylcholine receptor M2 antagonist AntagonistTarget: CHRM2 cholinergic receptor muscarinic 2✓ In ChEMBL and the Guide to Pharmacology
- Benign prostatic hyperplasiaPhase 3
- Lower urinary tract symptomPhase 3
- Alzheimer diseasePhase 2
- DementiaPhase 2
- Urgency urinary incontinencePhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1734, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7483, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Solifenacin Succinate
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 17 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Solifenacin Succinate
- ChEMBL
- CHEMBL1734
- DrugBank
- DB01591
- PubChem CID
- 154059
- CAS number
- 242478-37-1
- FDA UNII
- A8910SQJ1U
- Wikidata
- Q59575279
- Wikipedia
- Solifenacin
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Solifenacin Succinate
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
NCT07473310 · ClinicalTrials.gov ↗ · Overactive Bladder (OAB), Urge Incontinence
|
Phase 4 | Recruiting | Mansoura University | Egypt |
|
Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder
NCT05798403 · ClinicalTrials.gov ↗ · Overactive Bladder
|
Not applicable | Recruiting | Yin Ping | China |
|
Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet
NCT06201013 · ClinicalTrials.gov ↗ · Urinary Bladder, Overactive, Overactive Bladder, Urinary Incontinence, Urge
|
Not applicable | Recruiting | Children's Hospital of Chongqing Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Solifenacin Succinate
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Yin Ping | 1 |
| Children's Hospital of Chongqing Medical University | 1 |
| Mansoura University | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Solifenacin Succinate trials
How many clinical trials are testing Solifenacin Succinate?
3 current trials in our China and Egypt registers name Solifenacin Succinate as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Solifenacin Succinate trials recruiting patients?
Yes. 3 of the 3 trials are recruiting: 2 with sites in China and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Solifenacin Succinate clinical trials?
Yin Ping (1), Children's Hospital of Chongqing Medical University (1) and Mansoura University (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Solifenacin Succinate works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Solifenacin Succinate works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Solifenacin Succinate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.